Eda Yilmaz Akcay

Eda Yilmaz Akcay

Auto-generated profile, based on publicly available information

Eda Yilmaz Akcay

Department of Pathology, Baskent University Faculty of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
MAMelahat Atasever
Melahat Atasever
BYBulent Yilmaz
Bulent Yilmaz
GDGulay Dilek
Gulay Dilek
EAEda Yilmaz Akcay
Eda Yilmaz Akcay
SKSefa Kelekci
Sefa Kelekci

1 October 2019 in European Journal of Breast Health
Verified
Journal Article
Closed access
STSehnaz Tezcan
Sehnaz Tezcan
NUNihal Uslu
Nihal Uslu
FOFunda Ulu Ozturk
Funda Ulu Ozturk
EAEda Yilmaz Akcay
Eda Yilmaz Akcay
TTTugan Tezcaner
Tugan Tezcaner
Eur J Breast Health AVES | Copyright © 2017 Türkiye Meme Hastalıkları Dernekleri Federasyonu |

30 August 2023 in Düzce Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
AAAlev Ok Atilgan
Alev Ok Atilgan
MTMerih Tepeoğlu
Merih Tepeoğlu
EAEda Yilmaz Akçay
Eda Yilmaz Akçay
LHLeyla Hasanali̇yEva
Leyla Hasanali̇yEva
DKDalokay Kiliç
Dalokay Kiliç
HÖHandan Özdemi̇r
Handan Özdemi̇r
Aim: The current study aimed to investigate apoptotic proteins such as caspase-3 and GRIM-19 protein expression in non-mucinous lung adenocarcinomas and their clinicopathologic significance. Material and Methods: This study was performed on 81 patients diagnosed with non-mucinous lung adenocarcinoma between January 1, 2010, and June 1, 2020. Immunohistochemical analysis was performed to examine the expressions of caspase-3 and GRIM-19, and the association between these proteins and clinicopathological parameters was investigated. Results: Caspase-3 nuclear positivity was more common in high-grade non-mucinous lung adenocarcinomas (p<0.001). Caspase-3 cytoplasmic expression was stronger in tumors with advanced-stage (p=0.021) and lymph node metastases (p=0.020). GRIM-19 expression was low in tumors with high-grade non-mucinous lung adenocarcinomas (p=0.002), and tumors with lymphovascular invasion (p=0.021). The median follow-up time was 31.7 (range, 1-145 months. The overall 5-year survival rate of patients with low and high GRIM-19 expression tumors was 48% and 92%, respectively. GRIM-19 expression significantly affected the 5-year overall survival rate (p=0.008), but not the 5-year disease-free survival rate (p=0.368). Conclusion: We revealed a significant association between caspase-3 and GRIM-19 expressions and poor clinicopathologic features and prognosis. For the first time in the literature, we revealed an association between low GRIM-19 expression and worse clinical outcomes in patients with non-mucinous lung adenocarcinoma. Caspase-3 and GRIM-19 may become potential therapeutic targets and novel potential predictive biomarkers for non-mucinous lung adenocarcinoma patients.


1 September 2018 in Journal of Urological Surgery
Verified
Journal Article
Closed access
EKEnis Kervancıoğlu
Enis Kervancıoğlu
ADAyhan Dirim
Ayhan Dirim
EAEda Yılmaz Akçay
Eda Yılmaz Akçay